Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 9/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14446520 | 0.87 | CRHR1 (0.54) | GABRA2GABRB2ALDH1A1SMN1; SMN2CRHR1 | |
| SCHEMBL14446517 | 0.81 | CRHR1 (0.60) | SMN1; SMN2CRHR1MAPK1KMT2A | |
| SCHEMBL23494114 | 0.76 | MAPK1 (0.51) | GABRA2GABRB2ALDH1A1SMN1; SMN2ELANE | |
| SCHEMBL5389175 | 0.71 | GABRA2 (0.49) | GABRA2GABRB2ALDH1A1SMN1; SMN2SLC5A1 | |
| SCHEMBL14446526 | 0.71 | CRHR1 (0.63) | CRHR1 | |
| SCHEMBL28800164 | 0.70 | PDE4B (0.55) | ALDH1A1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL5384064 | 0.70 | CRHR1 (0.61) | CRHR1KMT2A | |
| SCHEMBL4503440 | 0.69 | GABRA2 (0.64) | GABRA2GABRB2SLC5A1SLC5A2MAPK1 | |
| SCHEMBL5383687 | 0.69 | CRHR1 (0.62) | ALDH1A1SMN1; SMN2CRHR1ELANEMAPK1 | |
| SCHEMBL14446523 | 0.68 | CRHR1 (0.54) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | claimed |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GABRA2 360/4885GABRB2 473/4885ALDH1A1 2593/4885 |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GABRA2 360/4885GABRB2 473/4885ALDH1A1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.